Merck Sharp + Dohme Corp.

Schering Corporation

Jinsong Hao

William J Greenlee

Andrew William Stamford

Bernard R Neustadt

Hong Liu

Samuel Chackalamannil

Craig D Boyle

Unmesh G Shah

Joel M Harris

Stephane L Bogen

Barbara A Pio

Michael W Miller

Shuwen He

Michael T Rudd

Harry R Chobanian

Dane James Clausen

Dexi Yang

Lan Wei

Dong Xiao

Yan Xia

Shawn P Walsh

Li Xiao

Santhosh Francis Neelamkavil

Ping Chen

Yan Guo

Deodial Guy Guiadeen

Charles Jayne

Shishi Lin

Dipannita Kalyani

Charles Lee Jayne

Dippanita Kalyani

The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Heteroaryl pyrrolidine and piperidine orexin receptor agonists

The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Bicycloheptane pyrrolidine orexin receptor agonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic heterocyclic compounds

Antidiabetic spirochroman compounds

The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient. 

Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes

Compounds of the Formula (I), where W represents CH or N; and Q represents &#x2014;CN, &#x2014;C(&#x2550;NOH)NH, &#x2014;CONHRor various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine Areceptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease. 

[object Object]

Compounds of the Formula I wherein Rand Rtogether with the carbon atoms to which they are bonded optionally form a further heteroaromatic ring of the formula (II) as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease. 

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein

Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, wherein

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Growing community of inventors

Belle Mead, NJ, United States of America

Jinsong Hao